Ovarian Cancer Treatment
Ovarian Cancer Treatment
Ovarian cancer treatment is built around one measurement — whether all visible disease can be removed — and one genotype question — whether PARP maintenance applies. Everything else, including the order of surgery and chemotherapy, follows from those two answers.
The route at each stage
Two questions organise everything: can all visible disease be removed in one operation, and does the genotype qualify for maintenance. The routes:
- Stage I — surgical staging with removal of the affected adnexa or full staging as indicated; fertility-sparing surgery where criteria are met; chemotherapy added for higher-risk histologies.
- Stages II–IIIC, resectable — primary debulking surgery aiming for no visible residual disease, followed by platinum-based chemotherapy.
- Stages II–IIIC, not fully resectable — neoadjuvant carboplatin–paclitaxel for three or four cycles, then interval debulking, then the remaining cycles.
- Stage IV — chemotherapy first in most cases, with surgery considered where a response makes complete removal achievable.
- All epithelial types — germline BRCA and HRD testing at diagnosis, so the maintenance decision is ready when chemotherapy ends.
The order is not a preference and not a ranking of centres: it is the resectability assessment converted into a sequence. The same operation, done after the right number of chemotherapy cycles, removes disease completely more often than one done prematurely against diffuse disease.
Debulking surgery
Debulking (cytoreductive) surgery for ovarian cancer is among the most extensive operations in this specialty: removal of uterus, both adnexa and omentum, stripping of peritoneal implants across the abdominal cavity, lymph node sampling, and — where disease requires it — bowel resection, diaphragm stripping or splenic procedures. The target is no visible residual tumour; where that is achieved, every subsequent treatment works from a stronger position, and the completeness of this operation is among the strongest factors under the team's control.
Two practical consequences follow. The operation belongs in centres that perform it regularly with the multi-organ support it needs — the question to ask any treating centre is how often this team achieves complete debulking. And because the operation can start as an unexpected finding during routine surgery, the rule for any planned ovarian surgery on a suspicious mass is to have it done by the team that can finish it properly.
Chemotherapy first: interval debulking
Where imaging and examination say a complete upfront resection is unlikely, the standard route is neoadjuvant carboplatin–paclitaxel for three or four cycles, reassessment imaging, interval debulking surgery, then the remaining cycles. This is a fully standard pathway in this cancer, not a fallback: the chemotherapy shrinks peritoneal disease to a volume the operation can clear, and the operation is done against smaller, less vascular disease.
What makes the pathway work is the reassessment point — imaging reviewed against the CA-125 trend, the operation timed between cycles rather than fitted around them. For international patients this matters in both directions: arriving for surgery without the resectability assessment risks the wrong first step, and arriving mid-chemotherapy for interval debulking requires the treating team to have the imaging and cycles in hand before the operating date is set.
Platinum-based chemotherapy
The backbone for epithelial ovarian cancer is carboplatin with paclitaxel, given every three weeks for six cycles in total, delivered intravenously — with intraperitoneal or dose-dense variants used in defined situations. The regimen's logic is that ovarian cancer is among the most platinum-sensitive of solid tumours, and the depth and durability of the platinum response is what the next phase builds on.
Side effects are known and managed: paclitaxel's neuropathy and hair loss, carboplatin's blood counts, and the allergic reactions that can develop with repeated carboplatin doses — which is why cycles are given where reactions can be handled, and why desensitisation protocols exist. The chemotherapy course is usually an outpatient one; its duration is set by the cycles, and the maintenance phase begins when it ends.
Maintenance: PARP inhibitors and bevacizumab
Maintenance is where the genotype earns its keep. PARP inhibitors — tablets taken at home after chemotherapy — exploit the DNA-repair defect that BRCA-mutated and HRD-positive tumours carry: the cancer that could not repair chemotherapy damage cannot repair the PARP-inhibited damage either. For BRCA-mutated disease the evidence is strongest; HRD testing extends eligibility to a wider group. This phase can run for years and is monitored with blood counts and clinic reviews.
Bevacizumab — an antibody against tumour blood supply — is added to chemotherapy and continued as maintenance in defined situations, decided at the MDT from stage and risk features. The two maintenance approaches answer different questions and are combined with chemotherapy rather than with each other in standard use. What both share: the decision is made at diagnosis and prepared for throughout, which is why the genetic test belongs at the start.
Germ cell tumours and fertility
Germ cell tumours — of girls and young women — follow their own protocol and a different prognosis: BEP chemotherapy (bleomycin, etoposide, cisplatin) is highly effective even at advanced stages, and surgery is fertility-sparing as a rule, removing the affected ovary while keeping the uterus and the other ovary. Staging is simpler; lymph nodes are assessed; and treatment is measured in weeks rather than years.
The points worth knowing: fertility after BEP is usually preserved, with eggs or embryos frozen before treatment where time allows; follow-up is intensive because recurrence, when it happens, comes early and is still treatable; and these young patients are best treated where BEP toxicities — lung and kidney among them — are managed routinely. A germ cell diagnosis should not be read through the lens of epithelial disease; the rules are different, mostly in the patient's favour.
Fluid, nutrition and comfort
Three supportive measures carry real weight in this cancer. Ascites — fluid in the abdomen — is drained when it causes distension or breathlessness, and its recurrence is one of the findings that adjusts the plan. Nutrition is managed actively throughout, because the treatment suppresses appetite and the disease itself causes early satiety — a combination that loses weight quietly — and weight loss mid-course compromises both surgery and chemotherapy. Bowel obstruction, when advanced disease causes it, is managed medically or surgically depending on the situation — a decision the MDT makes with the patient rather than by default.
None of these is an afterthought: the ability to keep a patient strong enough for the next cycle or the operation is part of the treatment, and it is planned alongside it rather than improvised.
How the MDT decides
An ovarian cancer MDT puts four items on the table — the CT with the imaging itself, the CA-125 trend, the pathology or cytology, and the germline BRCA status — and answers three questions in order. First: operable upfront, or chemotherapy first? — the resectability assessment. Second: which protocol fits the type — epithelial, germ cell or stromal. Third: is the maintenance plan prepared — PARP eligibility, bevacizumab indications, the genetic counselling arranged.
The sequence matters because the first operation cannot be taken back and chemotherapy cycles cannot be inserted retrospectively. For international patients this translates into one instruction — send the imaging itself, not only the reports, before any irreversible step — and the written MDT assessment returns within 48 hours of the file being complete.